Nostrum Biodiscovery expands US presence with new office in Boston
Barcelona-based biotech company Nostrum Biodiscovery has opened a new office at the Cambridge Innovation Center (CIC) in Boston to mark its footprint in the US market. This milestone marks a strategic step in the company’s international growth plan.
Barcelona-based biotech company Nostrum Biodiscovery has opened a new office at the Cambridge Innovation Center (CIC) in Boston to mark its footprint in the US market. This milestone marks a strategic step in the company’s international growth plan.
v ongoing collaborations and foster new partnerships in areas such as nucleic acids, targeted protein degradation, antibody design, and drug discovery.
"Our goal is to stay closer to our strategic partners, accelerate joint projects, and increase the visibility of our technologies in a highly competitive environment” says Modesto Orozco, President and cofounder of Nostrum Biodiscovery.
Located at the Cambridge Innovation Center (CIC), in the heart of Boston’s biotech ecosystem, Nostrum Biodiscovery’s new office will serve as the base for leading their Business Development operations in North America, enabling closer interaction with biotechs, pharma partners, and academic institutions.
About Nostrum Biodiscovery
Cofounded in 2025 by professors Modesto Orozco and Víctor Guallar, Nostrum Biodiscovery is a spin-off of the Barcelona Supercomputing Center (BSC), the Institute for Research in Biomedicine (IRB Barcelona), the University of Barcelona and the Catalan Institution for Research and Advanced Studies (ICREA), with the mission of accelerating rational drug discovery by combining molecular modeling and artificial intelligence technologies.ç
Nostrum Biodiscovery supports biopharma partners from early research through to lead optimization, providing structure- and AI-based solutions to identify, design, and improve therapeutic candidates with greater precision and efficiency.